List of Excipients in Branded Drug CINRYZE

« Back to Dashboard

CINRYZE Excipient Strategy and Commercial Opportunities

Last updated: August 23, 2026

CINRYZE is a plasma-derived C1 esterase inhibitor used for routine prophylaxis against hereditary angioedema attacks. Its current excipient system is deliberately conservative: sodium citrate, sodium chloride and sucrose in a preservative-free lyophilized powder, reconstituted with sterile water. The strongest commercial opportunities are not new excipient claims alone. They are improved reconstitution, liquid stability, reduced administration burden, container-closure performance, and differentiated delivery systems.

What excipients are used in CINRYZE?

CINRYZE contains three principal excipients in its lyophilized drug product:

Component	Function in CINRYZE
Sodium citrate	Buffering and pH control
Sodium chloride	Tonicity and ionic-strength adjustment
Sucrose	Protein stabilizer and lyoprotectant
Sterile Water for Injection	Reconstitution diluent

The product is supplied as a sterile, preservative-free lyophilized powder. Each vial contains 500 units of human C1 esterase inhibitor. The reconstituted solution has a concentration of approximately 100 units/mL and is administered intravenously. The product is supplied with a separate diluent vial and transfer device under the U.S. presentation. [1]

The excipient strategy reflects the sensitivity of plasma-derived proteins to aggregation, oxidation, denaturation and interfacial stress. Sucrose supports protein stabilization during freezing and drying. Citrate provides buffering capacity, while sodium chloride helps control osmolality and ionic conditions.

CINRYZE does not rely on antimicrobial preservatives. That choice reduces the risk of preservative-related protein instability and avoids exposing patients to unnecessary excipient load in a chronic prophylactic product.

Why does CINRYZE use a lyophilized formulation?

Lyophilization improves the stability of a protein drug during storage and transport. It also allows a plasma-derived C1 inhibitor product to be distributed with a longer shelf life than many liquid biologic formulations.

The tradeoff is operational complexity. Patients or caregivers must:

1. Remove and inspect two vials.
2. Reconstitute the powder with the supplied diluent.
3. Mix without excessive agitation.
4. Transfer the solution into a syringe.
5. Administer the product intravenously.

For a hereditary angioedema patient receiving prophylaxis every three to four days, this process creates recurring time, training and adherence costs. A commercial reformulation that preserves protein integrity while reducing preparation steps could compete on convenience without changing the active ingredient.

Key formulation constraints

CINRYZE formulation development must control:

• Protein aggregation during manufacture and storage.
• Loss of activity during freeze-drying.
• Adsorption to glass, elastomer and transfer-device surfaces.
• Particulate formation after reconstitution.
• Microbial contamination during preparation.
• Variability in reconstitution time.
• Compatibility with intravenous administration.
• Stability after reconstitution and during infusion.

The excipient system must also remain compatible with plasma-derived manufacturing controls, viral inactivation steps, sterile filtration and the final container-closure system.

What commercial opportunities exist for CINRYZE excipients?

1. Ready-to-use liquid CINRYZE

The largest opportunity is a stable liquid formulation that eliminates reconstitution. A liquid C1 inhibitor product could improve home administration and reduce preparation errors.

Potential stabilizer platforms include:

• Sucrose or trehalose.
• Amino acids such as glycine or arginine.
• Nonionic surfactants such as polysorbate or poloxamer systems.
• Histidine, citrate or phosphate buffer systems.
• Low-concentration chelators where justified by oxidation-control data.

A liquid product would face a higher stability burden than the current lyophilized formulation. The key commercial question is whether the formulation can remain stable through its full shelf life under refrigerated conditions while preserving functional C1 inhibitor activity.

A liquid reformulation could support a 505(b)(2)-type strategy only if the product were legally positioned as a new drug product with an appropriate regulatory bridge. Because CINRYZE is a biologic, a new formulation would likely require a BLA supplement or other biologics-specific regulatory pathway rather than a conventional small-molecule 505(b)(2) filing.

2. Faster reconstitution

A lower-risk product improvement would retain lyophilization but reduce reconstitution time. Relevant approaches include:

• Optimized cake structure.
• Controlled residual moisture.
• Improved powder wetting.
• Lower surface-area-to-volume effects.
• Better transfer-device fluidics.
• Dual-chamber or integrated diluent systems.

This strategy could preserve the stability advantages of a dry product while addressing one of the main usability weaknesses.

3. Dual-chamber delivery systems

A dual-chamber vial or syringe could combine the lyophilized C1 inhibitor and diluent in a single presentation. The system would reduce vial transfers and limit contamination opportunities.

The commercial value would come from the combination of:

• Fewer preparation steps.
• Lower caregiver training requirements.
• Reduced need for separate diluent inventory.
• Better portability for home use.
• Potentially lower administration time.

The primary intellectual-property barrier would likely be the delivery system and container configuration rather than the individual excipients.

4. Excipient and container-closure optimization

CINRYZE is a protein product, so the container system is part of the formulation strategy. Potential development areas include:

• Low-binding syringe and vial materials.
• Elastomer closures with lower extractables and leachables.
• Silicone-oil reduction.
• Surface treatments that limit protein adsorption.
• Improved compatibility with automated transfer devices.
• Lower particulate generation during needle penetration.

These opportunities may be commercially valuable because they can be protected through device, packaging and manufacturing claims even where the core excipients are conventional.

5. Longer post-reconstitution stability

The FDA label directs prompt use after reconstitution. Extending allowable post-reconstitution storage could benefit home administration, infusion-center scheduling and emergency preparedness.

The development burden would include evaluation of:

• Potency retention.
• Aggregate formation.
• Subvisible particles.
• Microbial control.
• Container compatibility.
• Temperature excursions.
• Repeated handling under real-world home-use conditions.

A product with validated post-reconstitution stability could support a differentiated label and reduce waste from unused prepared doses.

How does CINRYZE compare with competing hereditary angioedema products?

CINRYZE competes against both plasma-derived and non-plasma-derived products. Excipient strategy differs according to route, dosing interval and product architecture.

Product	Active ingredient	Route	Product type	Main formulation or convenience distinction
CINRYZE	C1 esterase inhibitor	Intravenous	Plasma-derived protein	Lyophilized powder requiring reconstitution
Berinert	C1 esterase inhibitor	Intravenous	Plasma-derived protein	Primarily acute-treatment positioning
HAEGARDA	C1 esterase inhibitor	Subcutaneous	Plasma-derived protein	Subcutaneous prophylaxis with reconstituted product
RUCONEST	Recombinant C1 esterase inhibitor	Intravenous	Recombinant protein	Alternative manufacturing platform
TAKHZYRO	Lanadelumab	Subcutaneous	Monoclonal antibody	Extended dosing interval and prefilled presentations
ORLADEYO	Berotralstat	Oral	Small molecule	No parenteral excipients or reconstitution burden

[2-5]

CINRYZE’s principal weakness is administration burden relative to subcutaneous and oral alternatives. Its principal formulation advantage is the established lyophilized protein platform, which can offer storage robustness and a long commercial history.

HAEGARDA demonstrates the market value of moving C1 inhibitor prophylaxis to the subcutaneous route. Takhzyro and Orladeyo compete even more directly on convenience because they reduce or eliminate frequent intravenous preparation.

What patent opportunities protect CINRYZE formulation improvements?

The strongest patent opportunities are likely to concern combinations of formulation, process and device claims rather than broad claims to sodium citrate, sodium chloride or sucrose.

Potential formulation claim categories

A new CINRYZE-related patent program could target:

• Specific C1 inhibitor concentration ranges.
• Defined sucrose-to-protein ratios.
• Buffer and pH windows.
• Surfactant concentrations that reduce aggregation.
• Liquid formulations stable for a defined period.
• Lyophilized cakes with specified residual moisture.
• Reconstitution times below a defined threshold.
• Reduced particulate levels.
• Stabilization against freeze-thaw stress.
• Stability after dilution or transfer into an infusion container.

Broad claims to common excipients would face substantial novelty and obviousness risk. Narrow claims tied to a particular C1 inhibitor, activity-retention profile, impurity profile or manufacturing condition would generally have a stronger commercial rationale.

Potential device and packaging claims

Device claims could cover:

• Integrated powder-diluent systems.
• Transfer devices with reduced protein loss.
• Closed-system reconstitution.
• Dual-chamber syringes.
• Low-shear mixing mechanisms.
• Container closures that reduce coring and particulates.
• Prefilled or ready-to-administer systems.

These claims may provide a more defensible barrier than a conventional excipient composition because they can combine technical structure with measurable use benefits.

Manufacturing and process barriers

Plasma-derived C1 inhibitor products have additional process barriers. Relevant protected areas may include:

• Plasma pooling and fractionation.
• Purification and viral inactivation.
• Removal of activated proteases.
• Control of kallikrein-related impurities.
• Stabilization before filtration and filling.
• Aseptic lyophilization.
• Activity testing and lot-release methods.

A competitor cannot rely solely on an equivalent excipient system. It must also establish a compliant source and manufacturing process for the plasma-derived active ingredient.

What is the FDA regulatory status of CINRYZE?

CINRYZE was approved by the FDA in 2008 for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema. The FDA later expanded the indication to include pediatric patients aged 6 years and older. The current U.S. product is marketed by Takeda following Shire’s acquisition of ViroPharma and Takeda’s acquisition of Shire. [1, 6, 7]

CINRYZE is a biologic licensed under a biologics license application. It is not a conventional small-molecule product with an Orange Book patent listing. Patent and exclusivity analysis therefore requires review of biologic exclusivity, patent records, the Purple Book and court filings rather than relying only on Orange Book data.

When did CINRYZE lose regulatory exclusivity?

The statutory 12-year reference-product exclusivity period for a biologic approved in 2008 would have elapsed by 2020, subject to the applicable transition and pediatric-exclusivity rules. Regulatory exclusivity should therefore not be treated as the primary long-term barrier to competition.

The practical barriers remain more significant:

• Clinical and analytical comparability.
• Plasma supply.
• Manufacturing validation.
• Viral safety.
• Intravenous administration requirements.
• Physician and patient familiarity.
• Distribution contracts.
• Payer positioning against newer prophylactic therapies.

No Orange Book-style, definitive patent expiration date should be assigned to CINRYZE without a current review of issued U.S. patents, continuations, terminal disclaimers and litigation records. For a biologic, product-level competition can proceed through biosimilar or interchangeable-biologic pathways even though formulation and device patents may still affect launch timing.

What biosimilar and generic entry risks exist for CINRYZE?

Traditional generic entry is not the relevant pathway. CINRYZE is a biologic, so the principal U.S. risk is a biosimilar application under section 351(k) of the Public Health Service Act.

A biosimilar entrant would need to demonstrate high similarity to CINRYZE and no clinically meaningful differences in safety, purity and potency. The C1 inhibitor mechanism is established, but comparability may still be complicated by:

• Plasma-derived source material.
• Heterogeneous protein composition.
• Functional activity assays.
• Glycosylation and post-translational variation.
• Aggregates and process-related impurities.
• Viral-clearance validation.
• Differences in excipients or container systems.

A biosimilar could avoid some formulation patents by using a different excipient system, but it would still need to establish a suitable stability and administration profile. A differentiated subcutaneous or liquid product would likely compete as a separate product rather than as a direct interchangeable copy.

Which companies are challenging CINRYZE commercially?

The main commercial challengers are CSL Behring, Takeda’s own Takhzyro and Orladeyo franchises, Pharming and manufacturers developing alternative C1 inhibitor or kallikrein-pathway products.

The competitive pressure is segmented:

• Berinert competes in C1 inhibitor treatment.
• HAEGARDA competes in prophylactic C1 inhibitor therapy.
• Takhzyro competes through long-interval subcutaneous prophylaxis.
• Orladeyo competes through oral administration.
• RUCONEST competes through recombinant C1 inhibitor technology.

For excipient suppliers and formulation developers, the most attractive target is not necessarily a direct CINRYZE follow-on. A platform that supports stable plasma proteins, subcutaneous delivery or ready-to-use biologics may address several hereditary angioedema products and other replacement therapies.

What revenue exposure does CINRYZE create?

CINRYZE revenue is not generally reported as a separately disclosed product line in Takeda’s public financial reporting. The product contributes to Takeda’s rare-disease and hereditary-angioedema portfolio, but public filings typically aggregate the relevant products or report them within broader business categories. [7]

Commercial exposure is concentrated in:

• Chronic prophylaxis demand.
• Specialist prescribing.
• Home-infusion and specialty-pharmacy channels.
• Reimbursement changes.
• Patient switching to subcutaneous or oral therapies.
• Supply reliability for plasma-derived products.

A formulation upgrade that reduces preparation steps could protect revenue without requiring a new mechanism. A route-of-administration change would create a larger opportunity but would also require substantially more development, clinical, device and regulatory work.

How strong is the CINRYZE excipient strategy?

The existing excipient strategy is technically conservative and fit for a lyophilized plasma-derived protein. It is not strongly differentiated on the basis of commonly used excipients alone.

Its relative strengths are:

• Established stability platform.
• Preservative-free presentation.
• Compatibility with intravenous dosing.
• Long clinical and manufacturing history.
• Familiarity among hereditary angioedema specialists.

Its weaknesses are:

• Reconstitution burden.
• Intravenous administration.
• Limited convenience relative to subcutaneous and oral competitors.
• Potentially narrow room for composition-of-matter excipient claims.
• Dependence on specialized plasma-derived manufacturing.

The most defensible commercial strategy is a package of formulation, device, container and process improvements. A single patent directed only to sucrose, citrate or sodium chloride would likely provide limited protection.

Key Takeaways

• CINRYZE uses sodium citrate, sodium chloride and sucrose in a preservative-free lyophilized formulation.
• The main commercial weakness is reconstitution and intravenous administration, not the basic excipient selection.
• Ready-to-use liquid, dual-chamber and faster-reconstitution presentations offer the clearest product opportunities.
• Device, container-closure, post-reconstitution stability and manufacturing claims may be more valuable than broad excipient claims.
• CINRYZE’s U.S. biologic exclusivity period has elapsed, but biosimilar entry remains technically difficult because of plasma-derived source material and functional comparability requirements.
• HAEGARDA, Takhzyro and Orladeyo create the strongest competitive pressure on convenience and dosing burden.
• CINRYZE revenue is not separately reported in a way that permits a reliable standalone exposure estimate from public filings.

FAQs

Can CINRYZE excipients be replaced with trehalose?

Potentially, but replacement would require comparative stability, potency, aggregation, particulate and safety data. Trehalose could support lyophilization, but it would not automatically improve the product’s regulatory or commercial profile.

Is a liquid CINRYZE formulation commercially feasible?

It is technically feasible as a development concept, but liquid stability would need to match the current product’s shelf-life, potency and impurity profile. The strongest value proposition would be elimination of reconstitution.

Does CINRYZE have an Orange Book patent?

CINRYZE is a biologic, not a conventional small-molecule product. Orange Book analysis is therefore insufficient. Relevant protection must be assessed through biologic exclusivity, patent records, the Purple Book and litigation documents.

Would an excipient change create a biosimilar or a new product?

The answer depends on the development and regulatory pathway. A product with the same active ingredient but materially different formulation, route or device may be developed as a distinct biologic product rather than an interchangeable biosimilar.

Which CINRYZE formulation improvement has the highest commercial value?

An integrated, ready-to-use or substantially simplified presentation has the highest likely commercial value because it directly addresses the product’s recurring home-administration burden.

References

1. U.S. Food and Drug Administration. (2023). CINRYZE prescribing information. https://www.accessdata.fda.gov
2. CSL Behring. (2023). HAEGARDA prescribing information. https://www.fda.gov
3. Takeda Pharmaceuticals. (2024). TAKHZYRO prescribing information. https://www.accessdata.fda.gov
4. BioCryst Pharmaceuticals. (2024). ORLADEYO prescribing information. https://www.accessdata.fda.gov
5. Pharming Group N.V. (2024). RUCONEST prescribing information. https://www.accessdata.fda.gov
6. U.S. Food and Drug Administration. (2008). FDA approves Cinryze to prevent hereditary angioedema attacks. https://www.fda.gov
7. Takeda Pharmaceutical Company Limited. (2024). Annual report. https://www.takeda.com/investors/financial-results/